背景介绍 PCSK9 (Proprotein convertase subtilisin/kexin type 9) is known to function as a negative regulator of hepatic low-density lipoprotein receptors (LDLRs) by binding to the LDLR ectodomain. The D374T mutation is associated with hypercholesterolemia;  this form of PCSK9 is more potent at decreasing LDL uptake than wild-type PCSK9, most likely by increasing the binding affinity of PCSK9 for the LDLR. 产品介绍 The PCSK9(D374T) [Biotinylated]-LDLR Binding Assay Kit is designed for screening and profiling purposes. The key to this kit is the high sensitivity of detection of biotin-labeled PCSK9(D374T) by streptavidin-HRP. Only a few steps on a microtiter plate are required for the assay. First, LDLR ectodomain is coated on a 96-well plate. Next, PCSK9(D374T) is incubated with LDLR on the plate.  Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence, which can then be measured using a chemiluminescence reader.